USPTO Patent Grants - Therapeutics (A61P)

Drug Delivery System and Methods of Using the Same

The USPTO granted Axogen Corporation Patent US12599701B2 for a drug delivery system combining polydioxanone polymer with neuro-regenerative or immunosuppressive agents to form an implantable biomaterial. The patent includes 16 claims covering the method of combining, melting, and extruding the polymer with at least one immunophilin ligand. The invention is classified under CPC codes including A61P 25/02 (nervous system therapeutic activity) and A61L 27/54.

Biodegradable Lung Sealant PEG Hydrogel Patent Granted to Ethicon

USPTO granted patent US12599624B2 to Ethicon, Inc. for a rapid-setting biodegradable lung sealant comprising two multi-arm polyethylene glycol (PEG) compositions. The first PEG composition contains an alkaline buffer and the second contains a mildly acidic buffer, providing optimized setup time and extended working time. The formulation may include tocopherol as a radioprotectant and a colorant for improved visualization against lung tissue. The patent contains 22 claims and is classified under CPC codes A61K and A61P.

Shiseido Granted Patent for Skin Composition Formulations and Methods

USPTO granted Patent US12599623B2 to Shiseido Company, Limited on April 14, 2026. The patent covers body corrective cosmetic formulations and methods of use thereof, including skin treatment compositions. The application was filed on June 29, 2017 under Application No. 15638059 with 13 claims.

Method for Preparing Polydopamine Nanomotor Using Urease and Use of Same

USPTO granted Patent US12599571B2 to POSTECH Research and Business Development Foundation for a biocompatible polydopamine nanomotor using urease. The nanomotor is designed to infiltrate bladder walls in biological environments and remain inside the bladder for extended periods. The patent includes 10 claims covering the preparation method and therapeutic applications.

Probiotic Composition for Improving Soy Protein Proteolysis and Amino Acid Production Activity

USPTO granted patent US12599641B2 to Lactomason Co., Ltd. on April 14, 2026. The patent covers a probiotic composition that improves soy protein proteolysis and branched-chain amino acid production to prevent sarcopenia. The mixed bacterial strain formulation demonstrates enhanced self-aggregation, hydrophobicity, and intestinal adhesion compared to single-strain alternatives.

House Wellness Foods Probiotic Therapeutic Patent Granted

The USPTO granted Patent US12599638B2 to House Wellness Foods Corporation for a feed and composition comprising Lactobacillus plantarum strain L-137 and a fatty acid. The patent covers compositions for enhancing IL-12 production, immunostimulation, and bacteriostasis. The patent application was filed on September 21, 2021, with 7 claims granted.

Signum Biosciences Chia Seed Extract Patent Granted

The USPTO granted patent US12599642B2 to Signum Biosciences Inc on April 14, 2026. The patent covers compositions derived from Salvia hispanica (chia) seeds and methods of preparation and administration. The 18 claims span dermatological applications including skin care and sunscreen formulations. Third parties face no compliance obligations from this patent grant.

NLRP3 Modulators for Treating Interleukin 1β Diseases

USPTO granted patent US12599616B2 to Zydus Lifesciences Limited for novel substituted sulfonylurea and sulfoximineurea derivatives as NLRP3 modulators for treating interleukin 1β-mediated diseases and conditions. The patent contains 11 claims and 20+ CPC classifications spanning A61K, C07C, C07D, and A61P therapeutic categories.

Tumor Stroma Imaging Agent with FAP Targeting

USPTO granted patent US12599685B2 to Shanghai University of Medicine & Health Sciences for a tumor stroma imaging agent targeting fibroblast activation protein (FAP). The imaging agent exhibits high affinity for FAP, high uptake for malignant tumors with high FAP expression, and high sensitivity and specificity for tumor diagnosis. The patent covers the chemical structure where R is hydrogen or fluorine, and claims the agent's use for malignant tumor diagnosis and treatment with prolonged half-life.

Megmilk Snow Brand - US12599639B2 Joint Function-Improving Composition Patent

USPTO granted patent US12599639B2 to MEGMILK SNOW BRAND CO., LTD. for a joint function-improving composition containing bacterial cells and/or cultures of Lactobacillus, Lactococcus, Streptococcus, or Bifidobacterium genera combined with a joint function-improving agent. The composition targets prevention or treatment of osteoarthritis and rheumatoid arthritis through chondrocyte growth promotion and suppression of inflammation, cartilage degradation, pain, and neuronal outgrowth factors. The patent covers food, drink, feed, and pharmaceutical applications.

Serum Exosome With High Osteogenesis and High Angiogenesis for Bone Defect Repair

USPTO granted Patent US12599630B2 to Peking University School and Hospital of Stomatology for a serum exosome composition with high osteogenesis and high angiogenesis for bone defect repair. The patent covers exosomes derived from serum during fracture recovery period (weeks 2-5 post-fracture) and methods of preparing and using them for bone defect repair. The patent contains 5 claims.

Treatments for Ocular Neovascularization

USPTO granted patent US12599680B1 to 4D Molecular Therapeutics Inc. covering compositions and methods for treating ocular neovascular diseases such as wet age-related macular degeneration. The patent contains 24 claims and expires August 14, 2045.

Halozyme Hypercon Therapeutic Biologics Delivery Patent US12600763B2

USPTO granted patent US12600763B2 to Halozyme Hypercon, Inc. covering compositions and methods for delivering therapeutic biologics for disease treatment. The patent comprises 18 claims for particles containing therapeutic biologics suspended in a liquid carrier, with priority to an August 2022 filing date.

Tulane Patent for Therapeutic Compound Conjugates US12599674B2

The USPTO granted Patent US12599674B2 to The Administrators of the Tulane Educational Fund covering inventive therapeutic compound conjugates, pharmaceutical compositions, and related methods of treatment and manufacture. The patent, filed June 24, 2025, under application 19247100, contains 23 claims classified under A61K and A61P (oncology).

Cancer Vaccine Patent hESCs TLR3 Adjuvant Assigned to INSERM

USPTO granted patent US12599662B2 to INSERM for a cancer vaccine composition using irradiated human embryonic stem cells combined with a TLR3 adjuvant. The patent covers methods for treating cancers including breast cancer by inducing MHC-I presentation of antigens. The patent includes 16 claims.

USPTO Patent US12601742B2 for Endometrial Cancer Treatment Methods

USPTO granted patent US12601742B2 to Mayo Foundation for Medical Education and Research covering methods and materials for assessing and treating endometrial cancer. The patent covers methods for identifying endometrial cancers likely to respond to particular cancer treatments by assessing combinations of mutations and expression levels, such as platinum-based therapies. The patent contains 22 claims.

Nestlé Granted Patent for Green Coffee Insulin Treatment Composition

USPTO granted Patent US12599643B2 to Societe des Produits Nestle S.A. for green coffee-based compositions comprising hydrolysed chlorogenic acid for improving insulin profile. The patent covers compositions for treating or preventing disorders linked to increased plasma postprandial insulin, including esterase treated decaffeinated green coffee extract with 40-200 mg daily dosage. The patent contains 16 claims and was filed March 27, 2020.

Thrombolytic Agents for Intravascular Clots - US12599653B2

The USPTO granted Patent US12599653B2 to Jinis Co., Ltd. for a thrombolytic agent comprising a dual-domain polypeptide with a thrombo-recognition domain and a thrombolytic domain effective for dissolving intravascular thrombus. The patent covers a pharmaceutical composition designed to prevent and treat thrombosis with reduced bleeding side effects compared to conventional thrombolytic therapies. The patent application was filed October 19, 2020, under Application No. 17770795.

CyPep-1 Peptide Composition for Treating Neoplastic Lesions

USPTO granted patent US12599646B2 to CYTOVATION ASA covering a pharmaceutical composition comprising therapeutic peptide CyPep-1 for treating neoplastic lesions, particularly warts. The patent, with 16 claims, was filed on March 10, 2020, and includes CPC classifications related to peptide formulations and therapeutic applications.

Acellular Amniotic Fluid for Ischemic Injury Treatment

USPTO granted patent US12599635B2 to University of Utah Research Foundation covering compositions and methods for treating ischemic injuries using acellular amniotic fluid (acAF). The patent names inventors Hadi Javan, Craig H. Selzman, Young Sook Lee, Jo-Anna Reems, and Jan L. Pierce, and includes 31 claims. The patent application was filed March 22, 2021 under application number 17912730.

US12599620B2 - Chronic Fatigue Syndrome Plasma Cell Inhibitor Treatment Method

The USPTO granted Patent US12599620B2 to Vestlandets Innovasjonsselskap AS covering a method for treating chronic fatigue syndrome using inhibitory or cytotoxic agents against plasma cells. The patent also claims combinations of plasma cell-targeting agents with B-cell depleting agents or B-cell activation inhibitors. The patent application was filed on August 31, 2020, under application number 17638453, and contains 3 claims.

Cytotoxic Imidazopyridine Compounds and Their Use in Therapy

The USPTO granted Patent US12599676B2 to MyricX Pharma Limited for cytotoxic imidazo[1,2-A]pyridine compounds and their therapeutic use. The patent covers compounds of formula (I) classified under A61P 35/00 for cancer therapy. The application (19072750) was filed March 6, 2025, and the patent contains 23 claims.

Demethylating Agent Melanoma Treatment Method Using STING Signaling Enhancement

USPTO granted patent US12599621B2 to H. Lee Moffitt Cancer Center covering methods for enhancing anti-tumor T cell responses in melanoma subjects with defective STING signaling using demethylating agents. The patent, filed January 21, 2021, includes claims to methods of treatment involving demethylating agents, STING agonists, and tumor infiltrating lymphocytes. Inventors: James Mulé, Rana Falahat, Glen Barber.

Integrin α10-Selected MSCs Treat Skin Defects

USPTO granted patent US12599633B2 to Xintela AB covering integrin α10-selected mesenchymal stem cell compositions for treating skin defects, with 20 claims. The patent protects cell populations and culture conditions that enhance viability and regenerative function in wound healing applications.

Method of Obtaining Pharmaceutical Agent Inhibiting HeLa Cervical Cancer Cells

USPTO granted Patent US12599626B2 to LLC 'Laboratory of Innovative Technologies' on April 14, 2026. The patent covers a method for producing a pharmaceutical agent for inhibiting proliferation of HeLa cervical cancer cells using metal powder obtained via electric wire explosion of low-carbon steel. The invention involves exploding wire with specific energy of 7-18 KJ/g in carbon monoxide, followed by passivation, mixing with RPMI-1640 nutrient medium, and phase separation to produce the therapeutic agent.

US12599617B2 Methods of Treating Head and Neck Cancers with Hemp Extract Containing CBD

The USPTO granted Patent US12599617B2 to Dove Innovation Pty Limited covering methods of treating head and neck cancers using compositions containing hemp-derived CBD. The patent, with 17 claims, specifically covers mucosal formulations of cannabis extract for cancer treatment. Inventors include Alexandra M. Capano, Pradeep Singh Tanwar, and Alex Nance.

US12599625B2 - Nitrous Oxide Oxygen Inhalation Therapy for ARDS

The USPTO granted Patent US12599625B2 to Penland Foundation on April 14, 2026, covering nitrous oxide and oxygen inhalation therapy for treating ARDS and conditions caused by elevated cytokine levels. The patent, invented by Roland M. Williams, contains 22 claims classified under A61K 33/00 and A61P 11/16. The treatment method involves administering nitrous oxide and oxygen by inhalation before, during, and/or after ARDS occurs to address acute cytokine system activation from infections, injuries, or other conditions.

Therapy Efficacy Method via Tissue Analysis, Arion Diagnostics

USPTO granted Patent US12599349B2 to Arion Diagnostics, Inc. covering a method for determining therapeutic agent efficacy through non-invasive biological tissue characterization. The method involves measuring molecular structure of tissue at two time points and observing changes to determine efficacy. The patent includes 27 claims and covers therapeutic applications across multiple CPC classifications including oncology, immunology, and neurological disorders.

Halozyme US12600959B2 - Modified PH20 Hyaluronidase Polypeptides

USPTO granted Patent US12600959B2 to Halozyme, Inc. covering modified PH20 hyaluronidase polypeptides with enhanced stability and activity. The patent includes 15 claims spanning formulations, compositions, and uses thereof. Filing date was March 5, 2025, with application number 19071345.

Isoxazolo[5,4-H]quinazoline CDK Inhibitor Patent

USPTO granted patent US12600731B2 to Chengdu Cynogen Bio-Pharmaceutical Technology Co., Ltd. for isoxazolo[5,4-H]quinazoline compounds effective as cyclin-dependent kinase (CDK) inhibitors for treating cell proliferation disorders. The patent contains 23 claims and covers pharmaceutical compositions and methods of treating CDK-mediated diseases.

Benzazepine derivative for vasopressin receptor disease treatment

Benzazepine derivative for vasopressin receptor disease treatment

Pharmaceutical Compositions with NSAID and Fatty Acid Oxidase Inhibitor for Treating Infections, Inflammation, Aging

The USPTO granted patent US12599614B2 to MD VAULT LLC for pharmaceutical compositions combining non-steroidal anti-inflammatory drugs (NSAIDs) with fatty acid oxidation inhibitors for treating microbial infectious diseases, associated inflammatory disorders, and aging-related conditions. The patent, filed December 13, 2021, contains 9 claims and covers compositions including agents such as diclofenac (A61K 31/616), mefenamic acid (A61K 31/495), and phenylbutazone (A61K 31/192).

Methods of Treating Fuchs Endothelial Corneal Dystrophy After Descemetorhexis

USPTO granted patent US12599609B2 to Kowa Company, Ltd. for methods of treating Fuchs endothelial corneal dystrophy (FECD) following descemetorhexis. The patent covers medications promoting healing in FECD patients and contains 26 claims. The inventors are Gary Gordon and Kazuhito Suehira.

Methods for Treating Cardiac Valve Disease Using Pharmaceutical Compounds

The USPTO granted Patent US12599608B2 to The Regents of the University of California covering methods of treating cardiac valve disease, including calcific aortic valve disease (CAVD), by administering pharmaceutical compounds of Formulae I-X. The patent names Christina Theodoris and Deepak Srivastava as inventors and includes 4 claims covering therapeutic applications and compound identification methods.

Timolol Compositions for Glaucoma Treatment, Novaliq

USPTO granted patent US12599607B2 to Novaliq GmbH on April 14, 2026, covering pharmaceutical compositions comprising timolol (a β1-receptor blocker) combined with a semifluorinated alkane liquid vehicle for topical ophthalmic administration. The patented compositions are intended for treatment of glaucoma, elevated intraocular pressure, ocular hypertension, and associated symptoms. The patent contains 21 allowed claims.

PDE1 Inhibitors Treat Colon Cancer, USPTO Grant

The USPTO granted Patent US12599603B2 to Intra-Cellular Therapies, Inc. covering phosphodiesterase 1 (PDE1) inhibitors for the treatment of colon cancer and certain tumors. The patent, with inventors Peng Li and Robert Davis, claims 12 method-of-treatment claims. The application was filed on September 3, 2020.

2-AG Enhancing Compositions for Migraine Relief

The USPTO granted Patent US12599600B2 to Arizona Board of Regents on Behalf of the University of Arizona for compositions and methods enhancing 2-arachydonyl glycerol (2AG) activity to prevent and treat headaches, particularly migraines. The patent covers methods for reducing prostaglandin activity and includes claims for pharmaceutical compositions containing 2AG-enhancing compounds.

MEDICON Anti-inflammatory, Anti-cancer, and Anti-angiogenic Compounds Patent

The USPTO granted patent US12599599B2 to MEDICON PHARMACEUTICALS, INC. covering compounds of general Formula A-D-Y with anti-inflammatory, anti-cancer, and anti-angiogenic activity for treating inflammation, cancer, neurodegenerative diseases, and cardiovascular diseases. The patent includes pharmaceutical compositions, methods of making, and methods of use with 4 claims.

N-Benzhydrylacetamide Inhibitors of Jumanji Domain Histone Demethylases for Cancer Treatment

USPTO granted patent US12599597B2 to the University of Kentucky Research Foundation covering substituted N-benzhydrylacetamide inhibitors of Jumanji domain histone demethylases for treating cancer via Wnt signaling pathway inhibition. The patent includes 10 claims and covers compounds according to Formula I and II, along with methods of administering these compounds to subjects needing cancer treatment.

Vemurafenib Salts for Enteroviral Infection Treatment (US12599591B2)

USPTO granted Patent US12599591B2 to Jyväskylän yliopisto for N-(3-(5-(4-chlorophenyl)-1H-pyrrolo[2,3-b]pyridine-3-carbonyl)-2,4-difluorophenyl)propane-1-sulfonamide (vemurafenib) and pharmaceutical salts for treating enteroviral diseases. The patent contains 14 claims and is classified under CPC codes A61K 31/437 and A61P 31/16.

Veterinary Formulations Comprising Rapamycin and Methods of Using the Same for Treating Animal Disease

The USPTO granted Patent US12599590B2 to TriviumVet DAC covering veterinary formulations comprising rapamycin or rapalogs for treating animal diseases including cardiac dysfunction, hypertrophic cardiomyopathy, dilated cardiomyopathy, mitral valve disease, cancer, effects of aging, inflammatory disease, and viral infection in companion animals. The patent contains 15 claims and was filed on December 18, 2020.

Succinimide Anticonvulsants Treat Expressive Language Deficit in Autism

USPTO granted patent US12599581B2 to AMS Therapeutics covering a pharmacological method for treating expressive language deficit in autistic humans using succinimide anticonvulsants (ethosuximide, methsuximide, phensuximide). The patent contains 10 claims with application number 18621580 filed on March 29, 2024.

Indoline Derivatives for Disease Treatment

The USPTO granted patent US12599584B2 to Yissum Research Development Company of The Hebrew University of Jerusalem Ltd. covering indoline derivatives and pharmaceutical compositions for treating diseases associated with oxidative stress, immune response, NO release, and pro-inflammatory cytokines. The patent names Marta Weinstock-Rosin, Abraham Nudelman, and Shani Zeeli as inventors and was filed on January 19, 2017. This grant establishes intellectual property protection for the therapeutic applications of these indoline compounds.

Cenobamate Carbamate Combination Therapy Patent for Epilepsy Treatment

USPTO granted patent US12599585B2 to SK Biopharmaceuticals covering combination therapy using cenobamate [(1R)-1-(2-chlorophenyl)-2-(tetrazol-2-yl)ethyl] carbamate with antiepileptic drugs for preventing or treating neurological disorders such as epilepsy. The patent contains 5 claims and lists inventors Marc Kamin and Laurent Vernillet.

Biphenyl Derivative Antimicrobial Adjuvant Patent Granted

USPTO granted Patent US12599575B2 to Korea Research Institute of Bioscience and Biotechnology for an antimicrobial adjuvant containing biphenyl derivative compounds as active ingredients. The patent covers technology that enhances sensitivity of gram-negative bacteria to polymyxin antibiotics, potentially reducing required dosages and associated side effects such as nephrotoxicity. The patent includes 14 claims and was filed on January 28, 2022 under Application No. 18275475.

Cambridge Cognition Patent - Combination Therapy for Schizophrenia

The USPTO granted Patent US12594270B2 to Cambridge Cognition Limited on April 7, 2026. The patent covers a combined therapy comprising alpha-7 nicotinic acetylcholine receptor activators with 5-HT3 receptor inhibitory activity combined with 5-HT3 receptor activators for treating schizophrenic disorders. The patent contains 21 claims and names Kiri Granger and Jennifer Barnett as inventors.

Mitochondria-targeted atovagone compounds and methods for antitumor, antimicrobial, and antimalarial treatment

USPTO granted Patent US12594283B2 to The Medical College of Wisconsin, Inc. covering mitochondria-targeted Atovaquone compounds (Mito-ATO) and methods of using such compounds for antitumor, antimicrobial, and antimalarial treatment. The patent contains 22 claims and was filed on October 26, 2020.

Patent US12594280B2: Antiviral Compositions for Influenza Treatment

USPTO granted Patent US12594280B2 to Universite Claude Bernard Lyon 1 covering antiviral pharmaceutical compositions containing Etilefrine and Diltiazem for preventing and treating influenza virus infections. The patent includes 10 claims and covers the use of these compounds in veterinary and pharmaceutical compositions.

Methods for treating inflammatory skin conditions (minocycline)

USPTO granted Journey Medical Corporation Patent US12594252B2 covering methods of treating inflammatory skin conditions using reduced-dose minocycline compositions. The patent, with 39 claims, names six inventors including Swati Kulkarni and Rajeev Singh Raghuvanshi. The invention relates to administering a pharmaceutical composition comprising a reduced dose of minocycline to achieve effective plasma or interstitial fluid concentrations for treating inflammatory skin conditions.

SCYNEXIS patent for triterpenoid antifungals treating Pneumocystis pneumonia

The USPTO issued patent US12594266B2 to SCYNEXIS, INC. on April 7, 2026, covering eufumafungin derivative triterpenoid antifungal compounds and their use in treating or preventing Pneumocystis pneumonia (PCP). The patent includes 16 claims encompassing the compound structures, pharmaceutical compositions, and methods of treatment.